Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia

OBJECTIVES: This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia. METHODS: In 64 sites in the United States, Russia, Ukraine, Hungary, Romania, and Serbia, 477 outpatients (18–65 years; m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Schizophr Bull
Autores principales: Walling, David, Marder, Stephen R., Kane, John, Fleischhacker, W. Wolfgang, Keefe, Richard S. E., Hosford, David A., Dvergsten, Chris, Segreti, Anthony C., Beaver, Jessica S., Toler, Steven M., Jett, John E., Dunbar, Geoffrey C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2016
Materias:
Regular Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4753586/
https://ncbi.nlm.nih.gov/pubmed/26071208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbv072
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares